metabolomic-profiling-identifies-key-lipid-and-redox-alterations-in-methylmalonic-acidemia
Metabolomic Profiling Identifies Key Lipid and Redox Alterations in Methylmalonic Acidemia

Metabolomic Profiling Identifies Key Lipid and Redox Alterations in Methylmalonic Acidemia

Untargeted liquid chromatography-high resolution mass spectrometry has revealed extensive serum metabolic rewiring in patients with MUT-type methylmalonic acidemia, identifying 267 significantly dysregulated human endogenous metabolites compared to healthy individuals. Conducted as an exploratory investigation into severe methylmalonyl-CoA mutase deficiency, the metabolomic analysis uncovered 185 upregulated compounds alongside 82 downregulated compounds. The profiled molecules spanned multiple essential biochemical domains, prominently featuring altered amino acid concentrations, aberrant lipid species, diverse acylcarnitines, and distinctive intermediates indicative of chronic oxidative stress and mitochondrial impairment. Among the most affected pathways identified through systematic functional mapping were arachidonic acid metabolism, glutathione metabolism, nicotinate and nicotinamide metabolism, purine metabolism, and sphingolipid turnover. Although methylmalonic acid emerged exclusively within the patient cohort as the primary confirmatory marker, widespread secondary disruptions accompanied the enzymatic defect. These metabolomic alterations highlight candidate disease-associated biomarkers that offer deeper molecular insights into the systemic pathophysiology of this rare disorder while establishing preliminary biochemical targets for subsequent prognostic evaluation.

Methylmalonic acidemia represents one of the most frequently diagnosed organic acidemias and stands as an inherited metabolic disorder transmitted in an autosomal recessive pattern. The condition primarily stems from deleterious mutations within the MUT gene, which encodes the mitochondrial enzyme methylmalonyl-CoA mutase. Under normal physiological conditions, this mutase enzyme requires adenosylcobalamin as an essential cofactor to catalyze the isomerization of methylmalonyl-CoA into succinyl-CoA, a vital intermediate feeding directly into the tricarboxylic acid cycle. This enzymatic step plays a crucial role in the catabolism of specific amino acids, including valine, isoleucine, methionine, and threonine, as well as odd-chain fatty acids. Disruptions in mutase activity, which account for approximately sixty percent of clinical cases, trigger the toxic accumulation of methylmalonic acid and related acidic metabolites throughout circulating blood and peripheral tissues. This chronic accumulation precipitates mitochondrial dysfunction, reduces cellular adenosine triphosphate generation, exacerbates oxidative stress, and drives multisystem clinical damage encompassing chronic kidney disease, pancreatitis, cardiomyopathy, bone marrow suppression, and neurodevelopmental delays.

Clinical presentation in affected infants frequently emerges during early infancy with recurrent vomiting, profound dehydration, muscular hypotonia, lethargy, failure to thrive, and severe metabolic acidosis. Uncontrolled metabolic decompensations present life-threatening emergencies that can culminate in coma or death, with recent metabolomic studies indicating that acidosis during crises is driven by acidic intermediates of branched-chain amino acid catabolism rather than circulating methylmalonic acid alone. The condition belongs to inborn errors of metabolism, which encompass more than 1,400 identified disorders. In regions with high rates of parental consanguinity, such as Saudi Arabia where consanguinity rates range between fifty and eighty percent, the incidence of inborn metabolic errors is markedly elevated compared to global averages, reaching frequencies as high as one in 569 live births. While newborn screening using tandem mass spectrometry measures informative acylcarnitines such as propionylcarnitine and propionylcarnitine-to-acetylcarnitine ratios, conventional screening and confirmatory urine organic acid tests offer limited capacity to detect novel biomarkers reflecting nuanced disease pathophysiology.

To elucidate these unmapped biochemical alterations, researchers analyzed 54 serum samples archived within the Metabolomics Laboratory at the Genomic Medicine Center of Excellence at King Faisal Specialist Hospital and Research Centre in Riyadh. The study cohort comprised 27 pediatric and adolescent patients with MUT-confirmed methylmalonic acidemia alongside 27 healthy control subjects. The patient cohort had an average age of 15.63 ± 1.49 years, whereas the healthy controls averaged 26.85 ± 0.91 years, with comparable female representation across groups at 51.85 percent and 44.44 percent, respectively. Serum specimens were collected between 2019 and 2023 during routine clinic visits while patients remained in a non-fasting, metabolically stable state under standard care, including dietary protein restriction, medical formulas, and carnitine supplementation. Patients with documented renal impairment, evidenced by estimated glomerular filtration rates ranging from 15 to 59 milliliters per minute per 1.73 square meters, were excluded to minimize confounding influences within the primary analytical comparisons.

Metabolomic profiling commenced with the extraction of serum metabolites from fifty microliters of serum using a cold fifty-percent acetonitrile-methanol solvent mixture. Following vortexing at six hundred revolutions per minute for one hour at twenty-five degrees Celsius and refrigerated centrifugation at sixteen thousand revolutions per minute, dried supernatant residues were reconstituted for chromatographic separation. Separation was achieved on a reversed-phase ACQUITY UPLC XSelect column maintained at fifty-five degrees Celsius under a multi-step binary gradient combining acidified aqueous and organic mobile phases at 300 microliters per minute. Eluates were ionized using an electrospray ionization source operated in positive and negative modes coupled to an Xevo G2-S quadrupole time-of-flight mass spectrometer utilizing MSE data-independent acquisition. System stability and instrument performance were validated using pooled quality control samples interspersed throughout the analytical sequence, adhering to relative standard deviation thresholds of thirty percent or less, with raw spectral datasets deposited in the Metabolomics Workbench repository under study identifier ST003690.

Raw spectral data were processed using Progenesis QI software to execute retention time alignment, peak picking, and mass-to-charge deconvolution, detecting 29,685 ion features across ionization modes. After applying a moderated t-test to eliminate 2,194 age-dependent ion features and enforcing an eighty-percent frequency filter, 13,608 robust spectral features remained for comparative evaluation. Supervised multivariate modeling through partial least squares discriminant analysis and orthogonal partial least squares discriminant analysis established distinct sample clustering and robust group separation, confirmed by a one-hundred-permutation test yielding model fitness and predictive metrics of R2Y equal to 0.977 and Q2 equal to 0.814. Univariate volcano plot filtering employing a false discovery rate threshold of 0.05 and a two-fold change cutoff isolated 692 significantly dysregulated features. Database annotation against public repositories and subsequent exclusion of exogenous compounds isolated 267 endogenous human metabolites, with seventeen verified against an in-house chemical library under putative level-two identification standards.

Recognizing the baseline chronological age divergence between the adolescent patient cohort and adult control participants, investigators conducted analysis of covariance modeling incorporating age as a covariate. Following this adjustment, 219 of the 267 endogenous metabolites retained statistically significant associations with the disorder, an observation corroborated through supplementary spline-based non-linear analyses and restricted age-overlap sensitivity evaluations. Furthermore, Spearman correlation analyses demonstrated that 131 metabolites directly correlated with circulating methylmalonic acid concentrations within the patient group, reinforcing their direct relationship to metabolic disease severity. Prominent among the downregulated compounds were critical amino acids, specifically L-isoleucine and L-glutamine. The depletion of isoleucine directly reflects therapeutic protein restriction and medical formula regimens, whereas decreased glutamine concentrations indicate impaired anaplerotic replenishment of the tricarboxylic acid cycle. This anaplerotic deficit was mirrored by a significant reduction in nicotinic acid adenine dinucleotide, an intermediate whose synthesis relies on glutamine-dependent NAD+ synthetase, suggesting downstream consequences for cellular redox homeostasis and mitochondrial respiratory capacity.

Disturbances in cellular redox equilibrium and antioxidant defense mechanisms emerged as a central finding of the study, with glutathione metabolism remaining significantly disrupted following age-adjusted modeling. Glutathione synthesis depends upon adequate precursor pools of glutamate, cysteine, and glycine, and diminished glutamine availability appears to restrict glutamate provisioning for de novo tripeptide synthesis. In parallel with reduced antioxidant synthesis, the investigators detected marked reductions in S-formylglutathione, indicating compromised glutathione-dependent reactive aldehyde detoxification mechanisms that exacerbate cellular stress. Conversely, levels of pyroglutamic acid, a degradation product generated during intracellular glutathione turnover, were markedly elevated in patient serum, reflecting accelerated tripeptide consumption and compromised recycling under sustained oxidative pressure. Additional glutathione-related conjugates, including gamma-glutamylglycine, gamma-glutamylvaline, and glutamylisoleucine, also exhibited significant elevation among patients. Collectively, these coordinated alterations confirm that defective methylmalonyl-CoA mutase function precipitates profound secondary oxidative stress, depleted antioxidant buffering reserves, and chronic redox imbalance in methylmalonic acidemia.

The metabolomic survey also uncovered widespread lipid remodeling, characterized by striking elevations in bioactive inflammatory eicosanoids and circulating acylcarnitines. Patients exhibited significant upregulation of pro-inflammatory arachidonic acid cascade metabolites, including leukotriene B4, prostaglandins A1, E2, G1, G2, and H1, and multiple hydroxyeicosatetraenoic acids, indicating chronic inflammatory pathway activation. Concurrently, cytochrome P450-derived 11,12-epoxyeicosatrienoic acid was markedly increased, achieving a receiver operating characteristic area under the curve of 0.964, which may reflect a compensatory anti-inflammatory mechanism counteracting oxidative injury. Conversely, membrane-associated signaling lipids, including the prostaglandin F2alpha derivative MG(PGF2alpha/0:0/0:0), exhibited significant downregulation with a discriminatory area under the curve of 0.953. Circulating acylcarnitines, including undec-8-enoylcarnitine, tridec-6-enoylcarnitine, and octadecenoylcarnitine, were significantly elevated in patients, reflecting routine therapeutic L-carnitine supplementation alongside secondary impairments in mitochondrial fatty acid beta-oxidation. Upregulated purine byproducts, notably succinyladenosine, further illustrated widespread collateral disruptions in cellular purine nucleotide cycles and energy metabolism.

While these comprehensive profiling results illuminate candidate disease-associated biomarkers and expand mechanistic understanding of MUT deficiency, several methodological and biological limitations necessitate cautious interpretation. Because enrolled patients adhered to specialized clinical management consisting of severe protein restriction, medical amino acid formulas, and routine L-carnitine supplementation, the distinct contributions of therapeutic interventions versus intrinsic disease pathology cannot be completely disentangled. Additionally, although extensive age-adjusted sensitivity analyses preserved the primary metabolic signatures, residual confounding arising from the limited chronological overlap between adolescent patients and older controls cannot be wholly excluded. The retrospective utilization of serum aliquots collected over multiple years introduces potential storage effects on labile lipid mediators, while the exclusion of patients with overt nephropathy prevented full characterization of renal-mediated metabolic shifts. Consequently, these findings represent exploratory observations that require prospective validation within larger, age-matched, longitudinal cohorts of newly diagnosed, treatment-naive individuals before candidate biomarkers can transition into clinical practice.

Subject of Research: Untargeted serum metabolomic profiling in patients with MUT-confirmed methylmalonic acidemia

Article Title: Untargeted metabolomics reveals distinct metabolic profiles in MUT-type methylmalonic acidemia

Article References: Alsuhaymi, S., AlMalki, R. H., Al Mogren, M., Alodaib, A., Emwas, A.-H., Dasouki, M., Alfares, A., Jaremko, M., & Abdel Rahman, A. M. (2026). Untargeted metabolomics reveals distinct metabolic profiles in MUT-type methylmalonic acidemia. Molecular and Cellular Pediatrics, 13(1), Article 37. https://doi.org/10.1186/s40348-026-00250-3

Image Credits: AI Generated

DOI: 10.1186/s40348-026-00250-3

Keywords: methylmalonic acidemia, MUT gene, untargeted metabolomics, methylmalonyl-CoA mutase, liquid chromatography-mass spectrometry, glutathione metabolism, arachidonic acid metabolism, succinyladenosine, leukotriene B4, 11,12-epoxyeicosatrienoic acid, inborn errors of metabolism, organic acidemias, acylcarnitines, nicotinate and nicotinamide metabolism, mitochondrial dysfunction, redox imbalance, purine metabolism, biomarker discovery